上尿路尿路上皮癌临床治疗进展

陈金虎; 方卫华; 梁朝朝

doi:10.13201/j.issn.1001-1420.2021.05.018

上尿路尿路上皮癌临床治疗进展

- 安徽医科大学第一附属医院泌尿外科安徽医科大学泌尿外科研究所泌尿生殖系统疾病安徽省重点实验室(合肥, 230022)

详细信息

通讯作者: 梁朝朝,E-mail:urologistcjh@163.com

中图分类号: R737.14

收稿日期: 2020-06-19

Progress in clinical treatment of upper urinary tract urothelial carcinoma

- Department of Urology, First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Medical University, Anhui Province Key Laboratory of Genitourinary Diseases, Hefei, 230022, China

More Information

Corresponding author: LIANG Chaochao, E-mail: urologistcjh@163.com

Received Date: 19 June 2020

摘要

摘要: 上尿路尿路上皮癌(UTUC)指发生于肾盂及输尿管的尿路上皮恶性肿瘤。虽然发病率较低,但起病隐匿,侵袭性强且复发率高,随着对该疾病认识的不断深入,对临床诊疗中术前评估、手术及围手术期治疗和预防膀胱复发等方面提出新的思考和挑战。本文就UTUC患者肿瘤风险评估、手术技术以及新辅助和辅助治疗中腔内和全身治疗的最新临床进展作一综述。
- 上尿路尿路上皮癌 /
- 手术治疗 /
- 新辅助化疗 /
- 免疫治疗
Abstract: Upper urinary tract urothelial carcinoma(UTUC) refers to malignant tumors of the urinary tract that occur in the renal pelvis and ureter. Although the incidence is low, the onset is insidious, invasive, and the recurrence rate is high. With the deepening understanding of the disease, new thinking and challenges have been raised in the aspects of preoperative evaluation, surgery and perioperative treatment and prevention of bladder recurrence. This article reviews the latest clinical advances in cancer risk assessment, surgical techniques, and neoadjuvant and adjuvant therapy for UTUC patients.
- upper tract urothelial carcinoma /
- operation treatment /
- neoadjuvant chemotherapy /
- immunotherapy

HTML全文

参考文献(48)

[1]	Rouprêt M,Babjuk M,Compérat E,et al.European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma:2017 Update[J].Eur Urol,2018,73(1):111-122.
[2]	Krabbe LM,Eminaga O,Shariat SF,et al.Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma[J].J Urol,2017,197(3 Pt 1):580-589.
[3]	周利群,熊耕砚,李学松.中国人群上尿路尿路上皮癌诊疗策略选择和东西方差异[J].临床泌尿外科杂志,2019,34(2):83-87.
[4]	Lughezzani G,Burger M,Margulis V,et al.Prognostic factors in upper urinary tract urothelial carcinomas:a comprehensive review of the current literature[J].Eur Urol,2012,62(1):100-114.
[5]	Rouprêt M,Babjuk M,Compérat E,et al.European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma:2017 Update[J].Eur Urol,2018,73(1):111-122.
[6]	Margulis V,Puligandla M,Trabulsi EJ,et al.Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma[J].J Urol,2020,203(4):690-698.
[7]	Yin M,Joshi M,Meijer RP,et al.Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer:A Systematic Review and Two-Step Meta-Analysis[J].Oncologist,2016,21(6):708-715.
[8]	Sfakianos JP,Cha EK,Iyer G,et al.Genomic Characterization of Upper Tract Urothelial Carcinoma[J].Eur Urol,2015,68(6):970-977.
[9]	Petros FG,Qiao W,Singla N,et al.Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma[J].Urol Oncol,2019,37(4):292.e1-292.e9.
[10]	Wang LJ,Chou WC,Pang ST,et al.Risk Stratification of Upper Urinary Tract Urothelial Carcinoma Patients for Survival Prediction:A Simple Summation Scoring Method[J].J Cancer,2018,9(13):2284-2294.
[11]	袁易初,黄吉炜,蔡彪,等.肿瘤大小对806例行根治手术的上尿路尿路上皮癌患者预后的分析[J].临床泌尿外科杂志,2019,34(4):274-279.
[12]	袁易初,黄吉炜,蔡文等,非肌层浸润性膀胱癌病史或合并非肌层浸润性膀胱癌对行根治手术的上尿路尿路上皮癌患者预后的影响—上海仁济医院10年资料总结[J].临床泌尿外科杂志,2019,34(2):104-112.
[13]	Freifeld Y,Ghandour R,Singla N,et al.Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma[J].Urol Oncol,2019,37(10):758-764.
[14]	Seisen T,Peyronnet B,Dominguez-Escrig JL,et al.Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma:A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel[J].Eur Urol,2016,70(6):1052-1068.
[15]	Cutress ML,Stewart GD,Zakikhani P,et al.Ureteroscopic and percutaneous management of upper tract urothelial carcinoma(UTUC):systematic review[J].BJU Int,2012,110(5):614-628.
[16]	程嗣达,李万强,穆莉,等.全腹膜外途径膀胱瓣肾盂吻合自体肾移植术在上尿路尿路上皮癌治疗中的应用[J].北京大学学报(医学版),2019,51(4):758-763.
[17]	Krabbe LM,Westerman ME,Bagrodia A,et al.Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes:results of a current series and a review of the literature[J].Urol Oncol,2014,32(1):54.e19-e26.
[18]	Zhang S,Luo Y,Wang C,et al.Long-term oncologic outcomes of laparoscopic nephroureterectomy versus open nephroureterectomy for upper tract urothelial carcinoma:a systematic review and meta-analysis[J].Peer J,2016,4:e2063.
[19]	Peyronnet B,Seisen T,Dominguez-Escrig JL,et al.Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma:An European Association of Urology Guidelines Systematic Review[J].Eur Urol Focus,2019,5(2):205-223.
[20]	Simone G,Papalia R,Guaglianone S,et al.Laparoscopic versus open nephroureterectomy:perioperative and oncologic outcomes from a randomised prospective study[J].Eur Urol,2009,56(3):520-526.
[21]	Donin NM,Strauss-Ayali D,Agmon-Gerstein Y,et al.Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer:Safety and feasibility[J].Urol Oncol,2017,35(5):272-278.
[22]	Kleinmann N,Matin SF,Pierorazio PM,et al.Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101,a mitomycin-containing reverse thermal gel(OLYMPUS):an open-label,single-arm,phase 3 trial[J].Lancet Oncol,2020,21(6):776-785.
[23]	Barros AA,Browne S,Oliveira C,et al.Drug-eluting biodegradable ureteral stent:New approach for urothelial tumors of upper urinary tract cancer[J].Int J Pharm,2016,513(1-2):227-237.
[24]	Liourdi D,Kallidonis P,Kyriazis I,et al.Evaluation of the distribution of Paclitaxel by immunohistochemistry and nuclear magnetic resonance spectroscopy after the application of a drug-eluting balloon in the porcine ureter[J].J Endourol,2015,29(5):580-589.
[25]	Wu WJ,Ke HL,Yang YH,et al.Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?[J].J Urol,2010,183(1):56-61.
[26]	O'Brien T,Ray E,Singh R,et al.Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma:A Prospective,Multicentre,Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C(the ODMIT-C Trial)[J].Eur Urol,2011,60(4):703-710.
[27]	van Doeveren T,van Leeuwen PJ,Aben K,et al.Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma:The REBACARE-trial[J].Contemp Clin Trials Commun,2018,9:121-129.
[28]	Miyamoto K,Ito A,Wakabayashi M,et al.A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma(JCOG1403,UTUC THP Phase Ⅲ)[J].Jpn J Clin Oncol,2018,48(1):94-97.
[29]	Messing EM,Tangen CM,Lerner SP,et al.Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence:SWOG S0337 Randomized Clinical Trial[J].JAMA,2018,319(18):1880-1888.
[30]	Kaag MG,O'Malley RL,O'Malley P,et al.Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy[J].Eur Urol,2010,58(4):581-587.
[31]	Tavora F,Fajardo DA,Lee TK,et al.Small endoscopic biopsies of the ureter and renal pelvis:pathologic pitfalls[J].Am J Surg Pathol,2009,33(10):1540-1546.
[32]	Meng X,Chao B,Vijay V,et al.High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma[J].Urology,2019,129:146-152.
[33]	Kim DK,Lee JY,Kim JW,et al.Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma:A systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2019,135:59-65.
[34]	Birtle AJ,Chester JD,Jones RJ,et al.Results of POUT:A phase Ⅲ randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer(UTUC)[J].J Clin Oncol,2018,36(6_suppl):407-412.
[35]	Ning YM,Suzman D,Maher VE,et al.FDA Approval Summary:Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy[J].Oncologist,2017,22(6):743-749.
[36]	Rosenberg JE,Hoffman-Censits J,Powles T,et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm,multicentre,phase 2 trial[J].Lancet,2016,387(10031):1909-1920.
[37]	Balar AV,Galsky MD,Rosenberg JE,et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma:a single-arm,multicentre,phase 2 trial[J].Lancet,2017,389(10064):67-76.
[38]	Gopalakrishnan D,Koshkin VS,Ornstein MC,et al.Immune checkpoint inhibitors in urothelial cancer:recent updates and future outlook[J].Ther Clin Risk Manag,2018,14:1019-1040.
[39]	Plimack ER,Bellmunt J,Gupta S,et al.Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer(KEYNOTE-012):a nonrandomised,open-label,phase 1b study[J].Lancet Oncol,2017,18(2):212-220.
[40]	Balar AV,Castellano D,O'Donnell PH,et al.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer(KEYNOTE-052):a multicentre,single-arm,phase 2 study[J].Lancet Oncol,2017,18(11):1483-1492.
[41]	Bellmunt J,de Wit R,Vaughn DJ,et al.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J].N Engl J Med,2017,376(11):1015-1026.
[42]	Sharma P,Retz M,Siefker-Radtke A,et al.Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275):a multicentre,single-arm,phase 2 trial[J].Lancet Oncol,2017,18(3):312-322.
[43]	Ye D,Liu J,Zhou A,et al.Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma[J].Cancer Sci,2021,112(1):305-313.
[44]	Carthon BC,Wolchok JD,Yuan J,et al.Preoperative CTLA-4 blockade:tolerability and immune monitoring in the setting of a presurgical clinical trial[J].Clin Cancer Res,2010,16(10):2861-2871.
[45]	Galsky MD,Hahn NM,Albany C,et al.Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer[J].J Clin Oncol,2016,34(2_suppl):357-363.
[46]	Herbst RS,Arkenau HT,Santana-Davila R,et al.Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer,gastro-oesophageal cancer,or urothelial carcinomas(JVDF):a multicohort,non-randomised,open-label,phase 1a/b trial[J].Lancet Oncol,2019,20(8):1109-1123.
[47]	Bahleda R,Italiano A,Hierro C,et al.Multicenter Phase I Study of Erdafitinib(JNJ-42756493),Oral Pan-Fibroblast Growth Factor Receptor Inhibitor,in Patients with Advanced or Refractory Solid Tumors[J].Clin Cancer Res,2019,25(16):4888-4897.
[48]	Loriot Y,Necchi A,Park SH,et al.Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma[J].N Engl J Med,2019,381(4):338-348.